• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Play Eczema Counts Now!
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Awards Program
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • SPD/PeDRA Journal Club
        • PeDRA Pearls Podcast
        • Mentorship Program
        • 2023 Annual Conference
        • 2023 Dash for Discovery Fun Run/Walk
        • Early Investigator Support
        • Play Eczema Counts Now!
        • Events Calendar
        • Explore our educational catalog!

  • Research
        • Grants and Fellowships
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • PeDRA EDI Corner
        • View all open funding opportunities!

  • Membership
        • New to PeDRA? Apply Here
        • 2024 Membership Renewal
        • Member Dashboard
  • About
        • Mission, Vision, and Core Values
        • Leadership & Staff
        • Annual Reports & Financials
        • Awards Program
        • News Archive
        • Our Supporters
        • Our Membership
        • Member Spotlight
        • Our Committees
        • Getting to Know You
        • It’s Membership Renewal Time – Renew today!

  • Member Login

Pilot study of novel therapy for the treatment of disfiguring congenital melanocytic nevi

January 12, 2023 By Katherine Devenport



Principal Investigator:

Yakir Levin, MD, PhD
Massachusetts General Hospital

Overview:

Congenital melanocytic nevi (CMN), depending on their size and location, can result in significant psychosocial morbidity. The most disfiguring lesions are the most difficult to resect surgically. Non-surgical treatment — if any — must be tailored to the needs of the individual patient and their family and usually involves many interventions performed under general anesthesia. The possibility of recurrence and of treatment-associated scarring always exists. There is a need for treatment that improves the appearance of the lesions with fewer treatments and with less risk of scarring.

Melanocytes, the cells of which CMN are composed, are known to be more sensitive to cold temperatures than other skin cells such as keratinocytes and fibroblasts. Controlled cooling is therefore a potentially attractive option for treating CMN. This work aims to explore the potential role of topically applied controlled cooling to the treatment of CMN.

Status:

This project was funded by a 2022 PeDRA Research Grant.

Filed Under: Skin Tumors and Reactions to Cancer Therapies

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sign up to receive emails from PeDRA

Four Star Charity Navigator

Join PeDRA
Donate

Copyright © 2023 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy